Leah Cann
Stock Analyst at Brookline Capital
(2.07)
# 2,807
Out of 4,711 analysts
16
Total ratings
42.86%
Success rate
8.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Leah Cann
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEIP MEI Pharma | Maintains: Buy | $80 | $2.50 | +3,100.00% | 2 | May 23, 2023 | |
| CRBU Caribou Biosciences | Initiates: Buy | $19 | $1.80 | +955.56% | 1 | Feb 14, 2022 | |
| CCCC C4 Therapeutics | Initiates: Buy | $54 | $3.95 | +1,267.09% | 1 | Jun 24, 2021 | |
| AGIO Agios Pharmaceuticals | Assumes: Perform | n/a | $35.42 | - | 4 | Feb 20, 2019 | |
| EXEL Exelixis | Upgrades: Outperform | n/a | $33.29 | - | 2 | Feb 27, 2018 | |
| NTLA Intellia Therapeutics | Initiates: Perform | n/a | $12.18 | - | 1 | Jul 18, 2017 | |
| EDIT Editas Medicine | Initiates: Perform | n/a | $1.31 | - | 1 | Jul 18, 2017 | |
| CRSP CRISPR Therapeutics AG | Initiates: Perform | n/a | $40.72 | - | 1 | Jul 18, 2017 | |
| VSTM Verastem | Initiates: Outperform | $72 | $4.19 | +1,618.38% | 3 | Apr 13, 2017 |
MEI Pharma
May 23, 2023
Maintains: Buy
Price Target: $80
Current: $2.50
Upside: +3,100.00%
Caribou Biosciences
Feb 14, 2022
Initiates: Buy
Price Target: $19
Current: $1.80
Upside: +955.56%
C4 Therapeutics
Jun 24, 2021
Initiates: Buy
Price Target: $54
Current: $3.95
Upside: +1,267.09%
Agios Pharmaceuticals
Feb 20, 2019
Assumes: Perform
Price Target: n/a
Current: $35.42
Upside: -
Exelixis
Feb 27, 2018
Upgrades: Outperform
Price Target: n/a
Current: $33.29
Upside: -
Intellia Therapeutics
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $12.18
Upside: -
Editas Medicine
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $1.31
Upside: -
CRISPR Therapeutics AG
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $40.72
Upside: -
Verastem
Apr 13, 2017
Initiates: Outperform
Price Target: $72
Current: $4.19
Upside: +1,618.38%